Combination of TATE and PD-1 Inhibitor in Liver Cancer
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is a single center, open-label phase IIA study that investigates the preliminary
efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer
followed by a PD-1 checkpoint inhibitor (either nivolumab or pembrolizumab). Patients with
four types of cancers will be enrolled, hepatocellular carcinoma (HCC), metastatic colorectal
cancer (mCRC), metastatic gastric cancer and advanced non-small cell lung cancer. All
enrolled patients need to have liver lesions.